Figure 5From: Development of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor Western blot analysis of KIT activation (phosphorylated KIT) in parental line (C2) and three resistant sublines (TR1, TR2, TR3) after incubation with increasing concentrations of toceranib phosphate for 24 hours. Back to article page